DxS, Epigenomics Exercise Cross-Licensing Options for IVD Development
July 22, 2009
DxS, Epigenomics Exercise Cross-Licensing Options for IVD Development
The two companies have cross-licensed "certain technologies," enabling both firms to develop IVD products based on DNA methylation that use DxS' Scorpions technology.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- LabCorp's Acquisition of Genzyme Genetics Adds to Oncology Molecular Dx Assets
September 22, 2010 / Pharmacogenomics Reporter - With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - Epigenomics, DxS, Expand Cross-license Agreement
July 20, 2009 / GenomeWeb Daily News - DxS Hoping to Invite Companion Dx Opportunities by Developing Blood-based Genetic Tests with Exosome
June 24, 2009 / Pharmacogenomics Reporter - Epigenomics' Q1 Revenues Increase 46 Percent
May 8, 2013 / GenomeWeb Daily News